Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $6.5 million.

  • 10x Genomics' Other Non-Current Liabilities rose 2867.37% to $6.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.5 million, marking a year-over-year increase of 2867.37%. This contributed to the annual value of $6.5 million for FY2025, which is 2867.37% up from last year.
  • According to the latest figures from Q4 2025, 10x Genomics' Other Non-Current Liabilities is $6.5 million, which was up 2867.37% from $6.4 million recorded in Q3 2025.
  • 10x Genomics' 5-year Other Non-Current Liabilities high stood at $10.1 million for Q3 2023, and its period low was $3.0 million during Q4 2022.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $6.4 million (2025), whereas its average is $6.6 million.
  • As far as peak fluctuations go, 10x Genomics' Other Non-Current Liabilities soared by 47385.11% in 2021, and later plummeted by 6388.35% in 2022.
  • Quarter analysis of 5 years shows 10x Genomics' Other Non-Current Liabilities stood at $8.2 million in 2021, then plummeted by 63.88% to $3.0 million in 2022, then surged by 43.65% to $4.3 million in 2023, then rose by 17.64% to $5.0 million in 2024, then increased by 28.67% to $6.5 million in 2025.
  • Its Other Non-Current Liabilities was $6.5 million in Q4 2025, compared to $6.4 million in Q3 2025 and $6.1 million in Q2 2025.